New combo therapy aims to boost survival in esophageal cancer patients
NCT ID NCT06676449
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding immunotherapy to a precise type of radiotherapy (sparing tumor-draining lymph nodes) and chemotherapy can help adults with advanced esophageal cancer live longer without the disease getting worse. About 432 participants will receive either the combination or standard treatment. The goal is to see if the new approach is more effective and safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple supplement soothe Radiation-Damaged rectums?
- Can imaging reveal how radiation shapes marrow recovery?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can a video call replace a clinic visit for cancer patients on radiotherapy?